CCR 20th Anniversary Commentary: MAPK/ERK Pathway Inhibition in Melanoma-Kinase Inhibition Redux

Clin Cancer Res. 2015 Dec 15;21(24):5412-4. doi: 10.1158/1078-0432.CCR-14-3132.

Abstract

In the January 15, 2012, issue of Clinical Cancer Research, Kirkwood and colleagues published a study comparing the MEK inhibitor selumetinib with temozolomide in unselected metastatic melanoma. Although selumetinib did not improve survival or response, most responders had BRAF-activating mutations, and selumetinib has since demonstrated efficacy in BRAF-mutant melanoma. This study laid the groundwork for the evaluation of BRAF/MEK inhibitors in BRAF-mutant melanoma.

Publication types

  • Research Support, N.I.H., Extramural
  • Comment

MeSH terms

  • Animals
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology*
  • Benzimidazoles / administration & dosage*
  • Cell Proliferation / drug effects*
  • Extracellular Signal-Regulated MAP Kinases / drug effects*
  • Humans
  • Melanoma / drug therapy*

Substances

  • Benzimidazoles
  • Extracellular Signal-Regulated MAP Kinases